IP Library Granted Patent US 9,181,237
Granted Patent B2
US 9,181,237 · App. 14/504,906 · Granted Nov 10, 2015

Substituted berbines and their synthesis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,181,237
App. No.
14/504,906
Granted
Nov 10, 2015
Kind
B2
Abstract

The present invention provides substituted berbines, processes for the synthesis of substituted berbine compounds, as well as intermediates used in the synthesis of substituted berbine compounds. Also provided are methods for using the substituted berbines to inhibit cancer cell growth.

Claims (32)

1. A compound of Formula (V-1):

wherein:

R 1 R 2 , R 3 , and R 4 independently are hydrogen, halogen, OR 15 , NR 15 N 16 , nitro, cyano, thiol, hydrocarbyl, substituted hydrocarbyl, or together R 2 and R 3 along with the ring carbons to which they are attached form a ring comprising {—}O(CH 2 ) n O{—};

R 5 , R 6 , R 7 , and R 8 independently are hydrogen, halogen, OR 15 , NR 15 N 16 , nitro, cyano, thiol, hydrocarbyl, substituted hydrocarbyl, or together R 6 and R 7 along with the ring carbons to which they are attached form a ring comprising {—}O(CH 2 ) n O{—}; provided that at least two of R 6 , R 7 , and R 8 are other than methoxy;

R 9 , R 10 , R 11 , and R 12 independently are hydrogen, hydrocarbyl, or substituted hydrocarbyl;

R 21 , R 22 , R 23 , R 24 , and R 25 independently are hydrogen, halogen, OR 15 , NR 15 N 16 , nitro, cyano, thiol, hydrocarbyl, or substituted hydrocarbyl;

R 15 and R 16 independently are hydrogen, hydrocarbyl, or substituted hydrocarbyl;

m is an integer of 0;

n is an integer from 1 to 3; and

the dashed lines represent optional double bonds.

2. The compound of claim 1 , wherein each of R 1 , R 4 , R 9 , R 10 , R 11 , and R 12 is hydrogen; R 2 and R 3 independently are hydrogen, halogen, hydroxy, alkyoxy, alkyl or together R 2 and R 3 form {—}O—CH 2 —O{—}; R 5 and R 8 independently are hydrogen, halogen, hydroxy, alkoxy, or alkyl; R 6 and R 7 independently are hydrogen, halogen, hydroxy, alkoxy, alkyl, aryloxy, substituted aryloxy, nitro, amino, amine, or amide; and R 21 , R 22 , R 23 , R 24 , and R 25 independently are hydrogen, halogen, hydroxy, alkoxy, alkyl, nitro, amino, or amine.

3. The compound of claim 1 , wherein the compound has Formula (V-1a):

wherein:

R 2 is hydroxy or alkyoxy and R 3 is hydrogen, or together R 2 and R 3 form {—}O—CH 2 —O{—};

R 5 and R 8 independently are hydrogen, halogen, hydroxy, alkoxy, or alkyl;

R 6 and R 7 independently hydrogen, halogen, hydroxy, alkyoxy, alkyl aryloxy, substituted aryloxy, nitro, amino, amine, or amide;

R 20 is hydrogen, halogen, hydroxy, alkoxy, alkyl, nitro, amino, or amine; and

m is 0.

4. The compound of claim 1 , wherein the compound has Formula (V-1b):

wherein:

R 2 is hydroxy or alkyoxy and R 3 is hydrogen, or together R 2 and R 3 form {—}O—CH 2 —O{—};

R 5 and R 8 independently are hydrogen, halogen, hydroxy, alkoxy, or alkyl;

R 6 and R 7 independently hydrogen, halogen, hydroxy, alkyoxy, alkyl aryloxy, substituted aryloxy, nitro, amino, amine, or amide;

R 20 is hydrogen, halogen, hydroxy, alkoxy, alkyl, nitro, amino, or amine; and

m is 0.

5. The compound of claim 1 , wherein the compound is chosen from the following compounds:

wherein:

R 2 is hydroxy or alkyoxy and R 3 is hydrogen, or together R 2 and R 3 form {—}O—CH 2 —O{—}

R 14 is alkyl or substituted alkyl.

R 15 is hydrogen or C 1 -C 6 alkyl;

X is halogen; and

Y and Z independently are hydrogen, halogen, hydroxy, alkoxy, alkyl, nitro, amino, or amine.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 039237, FRAME 0147 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0902 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →